Premium
p53 protein expression and oestrogen and progesterone receptor status in invasive ductal breast carcinomas
Author(s) -
IoakimLiossi A.,
Karakitsos P.,
Markopoulos C.,
Aroni K.,
Athanassiadou P.,
Delivelioti K.,
Athanassiades P.,
Vaiopoulos G.
Publication year - 2001
Publication title -
cytopathology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.512
H-Index - 48
eISSN - 1365-2303
pISSN - 0956-5507
DOI - 10.1046/j.1365-2303.2001.00315.x
Subject(s) - progesterone receptor , malignancy , medicine , breast cancer , receptor , oestrogen receptor , immunohistochemistry , oncology , mammary gland , ductal carcinoma , cancer research , cancer , estrogen receptor
p53 protein expression and oestrogen and progesterone receptor status in invasive ductal breast carcinomas The p53 protein expression and oestrogen and progesterone receptors status was investigated in correlation to the grade of malignancy of primary breast carcinomas. Our material constituted imprints from surgical biopsies of 75 invasive ductal breast cancer cases. The p53 protein expression was investigated immunocytologically using the monoclonal antibody p53 DO‐7 (DAKO). A biochemical DCC method was applied for the detection of oestrogen and progesterone receptors for all tumours. Fifty‐one percent of breast cancer cases were p53 protein positive. A statistically significant association of p53 protein expression and high tumour grade was found (χ 2 =23.72, d.f.=2, P < 0.001). A statistically significant association was also found between oestrogen and progesterone receptor positive cases and the grade of malignancy ( P < 0.001). A negative association between p53 protein expression and oestrogen (ER) and progesterone receptors (PgR) positivity was found. From our results it appears that it is possible to distinguish from grade II tumours two subgroups of cases, one with low malignancy potential and p53 (–), ER (+), PgR (+), and another subgroup with high malignancy potential and phenotype p53 (+), ER (–), PgR (–). The last subset of patients could actually benefit from adjuvant therapy.